These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 15866426)
1. Estradiol and medroxyprogesterone acetate regulated genes in T47D breast cancer cells. Mrusek S; Classen-Linke I; Vloet A; Beier HM; Krusche CA Mol Cell Endocrinol; 2005 May; 235(1-2):39-50. PubMed ID: 15866426 [TBL] [Abstract][Full Text] [Related]
2. Changes in protein tyrosine phosphatase type IVA member 1 and zinc finger protein 36 C3H type-like 1 expression demonstrate altered estrogen and progestin effect in medroxyprogesterone acetate-resistant and estrogen-independent breast cancer cell models. Pennanen PT; Sarvilinna NS; Purmonen SR; Ylikomi TJ Steroids; 2009; 74(4-5):404-9. PubMed ID: 19146866 [TBL] [Abstract][Full Text] [Related]
3. Glucocorticoid receptor activity discriminates between progesterone and medroxyprogesterone acetate effects in breast cells. Courtin A; Communal L; Vilasco M; Cimino D; Mourra N; de Bortoli M; Taverna D; Faussat AM; Chaouat M; Forgez P; Gompel A Breast Cancer Res Treat; 2012 Jan; 131(1):49-63. PubMed ID: 21336598 [TBL] [Abstract][Full Text] [Related]
4. Transcriptional profiles of progestogen effects in the postmenopausal breast. Wood CE; Register TC; Cline JM Breast Cancer Res Treat; 2009 Mar; 114(2):233-42. PubMed ID: 18404370 [TBL] [Abstract][Full Text] [Related]
5. Progestins regulate genes that can elicit both proliferative and antiproliferative effects in breast cancer cells. Purmonen S; Manninen T; Pennanen P; Ylikomi T Oncol Rep; 2008 Jun; 19(6):1627-34. PubMed ID: 18497975 [TBL] [Abstract][Full Text] [Related]
6. Mechanisms involved in the evolution of progestin resistance in human breast cancer cells. Murphy LC; Dotzlaw H; Wong MS; Miller T; Murphy LJ Cancer Res; 1991 Apr; 51(8):2051-7. PubMed ID: 1849041 [TBL] [Abstract][Full Text] [Related]
7. Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys. Wood CE; Register TC; Lees CJ; Chen H; Kimrey S; Cline JM Breast Cancer Res Treat; 2007 Jan; 101(2):125-34. PubMed ID: 16841178 [TBL] [Abstract][Full Text] [Related]
8. Effects of estradiol and progestogens on tumor-necrosis factor-alpha-induced changes of biochemical markers for breast cancer growth and metastasis. Seeger H; Wallwiener D; Mueck AO Gynecol Endocrinol; 2008 Oct; 24(10):576-9. PubMed ID: 19012101 [TBL] [Abstract][Full Text] [Related]
9. Effects of tibolone and its metabolites on Angiopoietin-1, Tie-2 and tumor necrosis factor-alpha mRNA in Ishikawa cells. Implication for tibolone's effects on the endometrium. Mirkin S; Archer DF Maturitas; 2007 Aug; 57(4):338-46. PubMed ID: 17478063 [TBL] [Abstract][Full Text] [Related]
10. Effects of estrogen on global gene expression: identification of novel targets of estrogen action. Charpentier AH; Bednarek AK; Daniel RL; Hawkins KA; Laflin KJ; Gaddis S; MacLeod MC; Aldaz CM Cancer Res; 2000 Nov; 60(21):5977-83. PubMed ID: 11085516 [TBL] [Abstract][Full Text] [Related]
11. Effects of estradiol and progestogens on human breast cells: regulation of sex steroid receptors. Chen FP; Chien MH; Chen HY; Huang TS; Ng YT Taiwan J Obstet Gynecol; 2013 Sep; 52(3):365-73. PubMed ID: 24075375 [TBL] [Abstract][Full Text] [Related]
12. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival. Menendez JA; Oza BP; Colomer R; Lupu R Int J Oncol; 2005 Jun; 26(6):1507-15. PubMed ID: 15870863 [TBL] [Abstract][Full Text] [Related]
13. COUP-TFI modulates estrogen signaling and influences proliferation, survival and migration of breast cancer cells. Le Dily F; Métivier R; Guéguen MM; Le Péron C; Flouriot G; Tas P; Pakdel F Breast Cancer Res Treat; 2008 Jul; 110(1):69-83. PubMed ID: 17674191 [TBL] [Abstract][Full Text] [Related]
14. Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate. Buchanan G; Birrell SN; Peters AA; Bianco-Miotto T; Ramsay K; Cops EJ; Yang M; Harris JM; Simila HA; Moore NL; Bentel JM; Ricciardelli C; Horsfall DJ; Butler LM; Tilley WD Cancer Res; 2005 Sep; 65(18):8487-96. PubMed ID: 16166329 [TBL] [Abstract][Full Text] [Related]
15. Dose-dependent changes of the ratio of apoptosis to proliferation by norethisterone and medroxyprogesterone acetate in human breast epithelial cells. Seeger H; Rakov V; Mueck AO Horm Metab Res; 2005 Aug; 37(8):468-73. PubMed ID: 16138258 [TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor expression is not regulated by estradiol or medroxyprogesterone acetate in endometrial carcinoma. Kim YB; Berek JS; Martinez-Maza O; Satyaswaroop PG Gynecol Oncol; 1996 Apr; 61(1):97-100. PubMed ID: 8626126 [TBL] [Abstract][Full Text] [Related]
17. Effect of medroxyprogesterone acetate on proliferation and cell cycle kinetics of human mammary carcinoma cells. Sutherland RL; Hall RE; Pang GY; Musgrove EA; Clarke CL Cancer Res; 1988 Sep; 48(18):5084-91. PubMed ID: 2970295 [TBL] [Abstract][Full Text] [Related]
18. Membrane-bound melatonin receptor MT1 down-regulates estrogen responsive genes in breast cancer cells. Girgert R; Hanf V; Emons G; Gründker C J Pineal Res; 2009 Aug; 47(1):23-31. PubMed ID: 19522736 [TBL] [Abstract][Full Text] [Related]
19. Regulation of vitamin D receptor expression via estrogen-induced activation of the ERK 1/2 signaling pathway in colon and breast cancer cells. Gilad LA; Bresler T; Gnainsky J; Smirnoff P; Schwartz B J Endocrinol; 2005 Jun; 185(3):577-92. PubMed ID: 15930183 [TBL] [Abstract][Full Text] [Related]
20. Progestins initiate a luminal to myoepithelial switch in estrogen-dependent human breast tumors without altering growth. Sartorius CA; Harvell DM; Shen T; Horwitz KB Cancer Res; 2005 Nov; 65(21):9779-88. PubMed ID: 16266999 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]